Analyst reports.

This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.

Analyst Reports 2023

Analyst Reports 2023
September 13th 2023

goetzpartners securities - Fully exploiting LAG3 oncology game changer. Reit Buy, A$2.88 tgt (Dr Chris Redhead)

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

September 10th 2023

CLSA - FY24 a pivotal year with key readouts ahead and cash runway to CY26. Mtn Buy, A$0.95 Tgt (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

August 31st 2023

Jefferies - FY23: I Say A Little Prayer; Mtn Buy and A$1 tgt (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

August 28th 2023

Baird - Efti Continues to Look More Promising than Anti-TIGIT; $7 tgt (Analysts: Joel L. Beatty and Benjamin E. Paluch)

For a copy of this research report please contact your Baird advisor

August 2nd 2023

Baird - Unique LAG-3 Agent with Fast Track Designation; Initiate OP, $7 tgt

For a copy of this research report please contact your Baird advisor

July 3rd 2023

Bell Potter - Cash Secured. Readouts 2H CY2023. (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

June 13th 2023

Wilsons Equity Research - Funding secured; bring on the readouts; Maintain Overweight (Analysts: Dr Melissa Benson and Dr Shane Storey)

May 29th 2023

goetzpartners securities - Efti-combo's boost efficacy of lung cancer standard of care; Reit Buy, A$2.88 tgt

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

May 29th 2023

Petra Capital - 2L HNSCC detailed results: Wait for ASCO; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

May 26th 2023

Wilsons Equity Research - Final 2L HNSCC data: still doubling ORR; Maintain Overweight (Analysts: Dr Melissa Benson and Dr Shane Storey)

May 25th 2023

Petra Capital - Triple combo data in NSCLC shows promise; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

May 24th 2023

Bell Potter - Efti's Efficacy - Strong Rationale for Prioritising NSCLC (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

May 18th 2023

Petra Capital - First OS look in NSCLC impresses; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

May 17th 2023

Maxim Group: Efti+Keytruda Leads to Positive Survival Data in 1L Lung Cancer; Raise tgt to $10, mtn Buy (Jason McCarthy, PhD)

For a copy of this analyst report please contact your Maxim advisor

May 17th 2023

Wilsons Equity Research - No longer a need to weigh up chemo; Maintain Overweight (Analysts: Dr Melissa Benson and Dr Shane Storey)

May 17th 2023

CLSA - Efti & Keytruda’s excellent adventure; OS data shows meaningful benefit in NSCLC, without need for chemo (Analyst: Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

May 3rd 2023

Wilsons Equity Research - Still a compelling opportunity; Maintain Overweight (Analysts: Dr Melissa Benson and Dr Shane Storey)

April 28th 2023

Petra Capital - Immutep Ltd (IMM) - 3QFY23 – Clinical Progress on all fronts; Retain Buy, A$1.28 tgt (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

April 19th 2023

Maxim Group - New Efti Trial Announced in Sarcoma; Moving into Neoadjuvant Setting; Buy, $8 tgt (Jason McCarthy, PhD)

For a copy of this analyst report please contact your Maxim advisor

April 5th 2023

Petra Capital - Immutep Ltd (IMM) - Efti activity in PD-1 refractory patients re-confirmed; Reit Buy, A$1.28 Tgt (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

April 4th 2023

goetzpartners securities - Potential standard of care in lung and other cancers; Reit Buy, Up Tgt to A$2.88

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

April 3rd 2023

Ladenburg Thalmann - Final 2L Lung Data Looks Fine; the Focus Is on 1L NSCLC; Reit Buy, $8.30 Tgt (Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor

April 3rd 2023

Wilsons Equity Research - Efti to enable expansion of Keytruda’s TAM; Maintain Overweight (Analysts: Dr Melissa Benson and Dr Shane Storey)

March 14th 2023

Maxim Group - New P2/3 AIPAC-003 Study Initiated with More Aggressive Dosing & OS Primary in Breast Cancer; Buy, $8 tgt (Jason McCarthy, PhD)

For a copy of this analyst report please contact your Maxim advisor

March 8th 2023

CLSA - Immutep: Defining year. Cash-runway through late stage head & neck readout and Lung Ph3 start. Retain Buy, A$1.25 tgt (Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

February 28th 2023

Petra Capital - Immutep Limited (IMM) - Accelerating clinical and manufacturing work (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

February 10th 2023

Petra Capital - Immutep - The stage is set for an explosive 2023; Reit Buy & lift TP by 8% to A$1.30 (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

January 31st 2023

Ladenburg Thalmann - One Asset and Multiple Opportunities; Reit Buy and $8.30 Target (Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor